Pfizer lashes out at ‘frustrating’ NICE decision on ALL drug Besponsa

21st August 2017 Uncategorised 0

Pfizer’s new targeted drug for the treatment of acute lymphoblastic leukemia (ALL) last week won FDA approval after already getting a nod by the EU. But U.K. cost watchdog NICE today snubbed Besponsa, eliciting a quick and heated response from the U.S. drugmaker.

More: Pfizer lashes out at ‘frustrating’ NICE decision on ALL drug Besponsa
Source: fierce